Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
Type:
Grant
Filed:
May 19, 2022
Date of Patent:
August 8, 2023
Assignee:
ARMGO Pharma, Inc.
Inventors:
Eugene E. Marcantonio, Mette Uhre Anby, Jérôme Binet
Abstract: The present disclosure relates to crystalline forms of the compound 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, pharmaceutical compositions comprising these compounds and uses thereof to treat diseases and conditions associated with Ryanodine Receptor (RyR) dysfunction, in particular cardiac and musculoskeletal disorders and diseases.
Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
Type:
Grant
Filed:
December 23, 2013
Date of Patent:
February 21, 2017
Assignees:
LES LABORATOIRES SERVIER, ARMGO Pharma, Inc.
Inventors:
Shixian Deng, Sandro Belvedere, Jiaming Yan, Donald Landry
Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
Type:
Grant
Filed:
November 11, 2013
Date of Patent:
October 7, 2014
Assignees:
Les Laboratoires Servier, ARMGO Pharma, Inc.
Abstract: The invention provides a process for preparing a 2,3,4,5-tetrahydro[1.4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reacting the [2-(acylaminoethyl)thio]arene with the aldehyde or multimer thereof and a base to form an [N-hydroxymethyl-2-[acylaminoethyl)thio]arene of formula then treating the [N-hydroxymethyl-2-(acylaminoethyl)thio]arene with the acid to form the 2,3,4,5-tetrahydro[1,4]benzothiazepine.
Type:
Application
Filed:
December 23, 2013
Publication date:
May 1, 2014
Applicants:
ARMGO PHARMA, INC., LES LABORATOIRES SERVIER
Inventors:
Shixian DENG, Sandro BELVEDERE, Jiaming YAN, Donald LANDRY
Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
Type:
Application
Filed:
November 11, 2013
Publication date:
March 27, 2014
Applicants:
ARMGO PHARMA, INC., LES LABORATOIRES SERVIER
Abstract: The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
Type:
Application
Filed:
April 18, 2013
Publication date:
October 24, 2013
Applicants:
ARMGO Pharma, Inc., LES LABORATOIRES SERVIER